Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2017-02-22 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2017-02-22 English
FORM 4 -
Director's Dealing
2017-02-22 English
NONE
Major Shareholding Notification
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 8, 2017, by Innoviva, Inc. It includes multiple items: Item 2.02 reports results of operations and financial condition for the quarter and full year ended December 31, 2016, but it only furnishes a press release and announces a conference call, not the full financial report itself. Item 5.03 discusses amendments to the company's bylaws related to governance, and Item 7.01 announces a board appointment. The document is primarily an announcement of events and changes, not a full financial report or detailed management discussion. The length is about 5944 characters, which is relatively short and consistent with an 8-K current report. The document does not contain comprehensive financial statements or detailed analysis, but rather announcements and references to other materials (press release, bylaws). Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like 8-Ks that do not fit other categories such as Annual Report, Interim Report, or Management Reports.
2017-02-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.